Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Tarantino, Paolo; Ajari, Ogheneochuko; Graham, Noah; Vincuilla, Julie; Parker, Tonia; Hughes, Melissa E.; Tayob, Nabihah; Garrido-Castro, Ana C.; Morganti, Stefania; King, Tari A.; Mittendorf, Elizabeth A.; Curigliano, Giuseppe; Lin, Nancy U.; Tolaney, Sara M.

doi:10.1016/j.ejca.2024.113920

European Journal of Cancer

2024

DOI: 10.1016/j.ejca.2024.113920

|View full text |Cite

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Paolo Tarantino,

Ogheneochuko Ajari,

Noah Graham

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Xie,

Zhang,

Liu

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Background During tumor progression, HER2 expression undergoes dynamic changes. Circulating tumor cells (CTCs) can be used to monitor HER2 expression in real-time and hold potential for clinical application. This study aimed to evaluate the consistency of HER2 expression between primary tumors and CTCs in patients with breast cancer (BC). Methods We used a previously established telomerase reverse transcriptase-based CTC detection method (TBCD) combined with anti-HER2 antibody to detect CTC and HER2-positive CTC (HER2 + CTC) in 4 ml of peripheral blood from patients with breast cancer prior to radiotherapy. The results indicated that the status of HER2 in CTC was inconsistent with the histological results. Results Discordance in HER2 status between primary tumor and CTC was observed in 32.6% of patients (kappa value = 0.325, p = 0.03). And among patients with histologically HER2-negative breast cancer, the detection rate of HER2 + CTC was 32.1% (9/28). Conclusions We found that the HER2 status of CTC in peripheral blood was inconsistent with the histological findings. Further research should explore the clinical significance of detecting HER2-positive CTCs, and it is desired that real-time HER2 status testing of CTCs could hold potential value for patients with breast cancer. Supplementary Information The online version contains supplementary material available at 10.1007/s12672-024-01663-0.

show abstract

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Xie,

Zhang,

Liu

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

The use of platelets as a clinical tool in oncology: opportunities and challenges

Bravaccini,

Boldrin,

Gurioli

et al. 2024

Cancer Letters

View full text Add to dashboard Cite

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆

Raghavendra,

Zakon,

Jin

et al. 2024

ESMO Open

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

Cited by 4 publications

References 38 publications

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer

The use of platelets as a clinical tool in oncology: opportunities and challenges

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆

Contact Info

Product

Resources

About